248 related articles for article (PubMed ID: 36027916)
1. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
Awad MM; Govindan R; Balogh KN; Spigel DR; Garon EB; Bushway ME; Poran A; Sheen JH; Kohler V; Esaulova E; Srouji J; Ramesh S; Vyasamneni R; Karki B; Sciuto TE; Sethi H; Dong JZ; Moles MA; Manson K; Rooney MS; Khondker ZS; DeMario M; Gaynor RB; Srinivasan L
Cancer Cell; 2022 Sep; 40(9):1010-1026.e11. PubMed ID: 36027916
[TBL] [Abstract][Full Text] [Related]
2. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Ott PA; Hu-Lieskovan S; Chmielowski B; Govindan R; Naing A; Bhardwaj N; Margolin K; Awad MM; Hellmann MD; Lin JJ; Friedlander T; Bushway ME; Balogh KN; Sciuto TE; Kohler V; Turnbull SJ; Besada R; Curran RR; Trapp B; Scherer J; Poran A; Harjanto D; Barthelme D; Ting YS; Dong JZ; Ware Y; Huang Y; Huang Z; Wanamaker A; Cleary LD; Moles MA; Manson K; Greshock J; Khondker ZS; Fritsch E; Rooney MS; DeMario M; Gaynor RB; Srinivasan L
Cell; 2020 Oct; 183(2):347-362.e24. PubMed ID: 33064988
[TBL] [Abstract][Full Text] [Related]
3. Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer.
Lin X; Tang S; Guo Y; Tang R; Li Z; Pan X; Chen G; Qiu L; Dong X; Zhang L; Liu X; Cai Z; Xie B
Cancer Immunol Immunother; 2024 Jan; 73(2):26. PubMed ID: 38280084
[TBL] [Abstract][Full Text] [Related]
4. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
5. Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC.
Leung CSK; Van den Eynde BJ
Cancer Cell; 2022 Sep; 40(9):903-905. PubMed ID: 36027917
[TBL] [Abstract][Full Text] [Related]
6. Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient.
Gao S; Wang J; Zhu Z; Fang J; Zhao Y; Liu Z; Qin H; Wei Y; Xu H; Dan X; Yang L; Xu Q
Immunotherapy; 2023 Feb; 15(2):57-69. PubMed ID: 36651232
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in neoantigen vaccines for treating non-small cell lung cancer.
Su S; Chen F; Xu M; Liu B; Wang L
Thorac Cancer; 2023 Dec; 14(34):3361-3368. PubMed ID: 37905603
[TBL] [Abstract][Full Text] [Related]
8. Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer.
McCann K; von Witzleben A; Thomas J; Wang C; Wood O; Singh D; Boukas K; Bendjama K; Silvestre N; Nielsen FC; Thomas G; Sanchez-Elsner T; Greenbaum J; Schoenberger S; Peters B; Vijayanand P; Savelyeva N; Ottensmeier C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361728
[TBL] [Abstract][Full Text] [Related]
9. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
D'Alise AM; Leoni G; Cotugno G; Siani L; Vitale R; Ruzza V; Garzia I; Antonucci L; Micarelli E; Venafra V; Gogov S; Capone A; Runswick S; Martin-Liberal J; Calvo E; Moreno V; Symeonides SN; Scarselli E; Bechter O
Clin Cancer Res; 2024 Jun; 30(11):2412-2423. PubMed ID: 38506710
[TBL] [Abstract][Full Text] [Related]
11. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
12. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
[TBL] [Abstract][Full Text] [Related]
13. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
[TBL] [Abstract][Full Text] [Related]
14. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
16. The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma.
Zhang Y; Lin Z; Wan Y; Cai H; Deng L; Li R
Front Immunol; 2019; 10():2472. PubMed ID: 31749795
[TBL] [Abstract][Full Text] [Related]
17. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
18. Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum.
Ingels J; De Cock L; Stevens D; Mayer RL; Théry F; Sanchez GS; Vermijlen D; Weening K; De Smet S; Lootens N; Brusseel M; Verstraete T; Buyle J; Van Houtte E; Devreker P; Heyns K; De Munter S; Van Lint S; Goetgeluk G; Bonte S; Billiet L; Pille M; Jansen H; Pascal E; Deseins L; Vantomme L; Verdonckt M; Roelandt R; Eekhout T; Vandamme N; Leclercq G; Taghon T; Kerre T; Vanommeslaeghe F; Dhondt A; Ferdinande L; Van Dorpe J; Desender L; De Ryck F; Vermassen F; Surmont V; Impens F; Menten B; Vermaelen K; Vandekerckhove B
Cell Rep Med; 2024 May; 5(5):101516. PubMed ID: 38626769
[TBL] [Abstract][Full Text] [Related]
19. Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma.
Peng S; Chen S; Hu W; Mei J; Zeng X; Su T; Wang W; Chen Z; Xiao H; Zhou Q; Li B; Xie Y; Hu H; He M; Han Y; Tang L; Ma Y; Li X; Zhou X; Dai Z; Liu Z; Tan J; Xu L; Li S; Shen S; Li D; Lai J; Peng B; Peng Z; Kuang M
Cancer Immunol Res; 2022 Jun; 10(6):728-744. PubMed ID: 35476700
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
